Thursday, January 8, 2026, San Francisco, California, 7:15 PM – 8:45 PM Pacific Time (10:15 PM – 11:45 PM Eastern Time)

Expert Second Opinion: Investigators Discuss the Optimal Management of HER2-Positive Gastrointestinal Cancers

A CME Symposium Held Adjunct to the 2026 ASCO® Gastrointestinal Cancers Symposium

Register for in-person Register for webcast

Program Schedule — Pacific Time
7:00 PM – 7:15 PM — Registration
7:15 PM – 8:45 PM — Educational Dinner Meeting

Location
San Francisco Marriott Marquis
780 Mission Street
San Francisco, California
Hotel Phone: (415) 896-1600

Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)

No registration fee is charged for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.  
 
Faculty
Haley Ellis, MD
Medical Oncologist
Mass General Brigham Cancer Institute
Harvard Medical School
Boston, Massachusetts

Eric Van Cutsem, MD, PhD
Professor of Medicine
Digestive Oncology
University Hospitals Leuven
Leuven, Belgium

Zev Wainberg, MD, MSc
Co-Director, GI Oncology Program
Director of Early Phase Clinical Research
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California
Moderator
Lionel A Kankeu Fonkoua, MD
Senior Associate Consultant
Assistant Professor of Oncology
Division of Medical Oncology, GI Cancer Program
Mayo Clinic
Rochester, Minnesota



This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.

Not an official event of the 2026 ASCO® Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.
Program Schedule — Pacific Time
7:00 PM – 7:15 PM — Registration
7:15 PM – 8:45 PM — Educational Dinner Meeting

MODULE 1: Biliary Tract Cancers (BTCs) — Dr Ellis

  • Prevalence of HER2 overexpression in advanced BTCs; indications and appropriate methods for HER2 testing
  • Efficacy and safety outcomes with trastuzumab deruxtecan (T-DXd) for HER2-expressing BTCs in the Phase II HERB trial and the BTC cohort of the Phase II DESTINY-PanTumor02 study
  • FDA approval of T-DXd for pretreated HER2-positive solid tumors; implications for BTC management
  • Published results from the pivotal Phase IIb HERIZON-BTC-01 trial investigating zanidatamab for previously treated unresectable, locally advanced or metastatic HER2-amplified BTCs
  • FDA approval of zanidatamab for previously treated unresectable or metastatic HER2-positive BTCs; practical integration and current clinical role
  • Spectrum, frequency and severity of adverse events associated with T-DXd and zanidatamab; optimal approaches to prevention and management
  • Ongoing Phase III studies, such as DESTINY-BTC01 and HERIZON-BTC-302, evaluating HER2-targeted strategies for patients with treatment-naïve, HER2-overexpressing advanced BTCs; anticipated completion dates

MODULE 2: Gastroesophageal Cancers — Dr Wainberg

  • Incidence of HER2-positive gastroesophageal cancers; appropriate strategies for ascertaining HER2 status
  • Published efficacy and safety data from the Phase III DESTINY-Gastric04 trial comparing T-DXd to ramucirumab/paclitaxel for patients with HER2-positive metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma who had previously received trastuzumab-based therapy
  • Optimal integration of T-DXd into the current management of advanced HER2-positive gastroesophageal tumors
  • Early results with T-DXd in combination with other systemic therapies for advanced HER2-positive gastroesophageal cancers (eg, from the DESTINY-Gastric03 trial)
  • Early findings with zanidatamab/chemotherapy as first-line treatment for advanced HER2-positive gastroesophageal adenocarcinoma
  • Emerging positive findings from the Phase III HERIZON-GEA-01 trial evaluating zanidatamab and chemotherapy with or without tislelizumab as first-line treatment for advanced HER2-positive gastroesophageal adenocarcinoma
  • Ongoing Phase III studies, such as DESTINY-Gastric05 and ARTEMIDE-Gastric01, evaluating T-DXd-containing regimens for patients with treatment-naïve, HER2-positive metastatic gastroesophageal cancers

MODULE 3: Colorectal Cancer (CRC) — Prof Van Cutsem

  • Frequency of HER2 overexpression or amplification in patients with metastatic CRC (mCRC); indications for, timing of and optimal approach to HER2 testing
  • Published data from the pivotal Phase II MOUNTAINEER trial evaluating tucatinib/trastuzumab for previously treated HER2-positive mCRC
  • FDA approval of tucatinib/trastuzumab and optimal incorporation into the mCRC treatment paradigm
  • Available efficacy and safety findings with T-DXd for HER2-expressing mCRC, such as those from the DESTINY-CRC01 and DESTINY-CRC02 trials
  • Ramifications of the tumor-agnostic approval of T-DXd for mCRC management
  • Other promising HER2-targeted strategies under investigation for mCRC

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastrointestinal cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appreciate the prevalence and clinical relevance of human epidermal growth factor receptor 2 (HER2) amplification or overexpression in various GI cancers, and consider the implications for biomarker assessment and clinical management.
  • Evaluate published clinical trial findings with HER2-directed therapies for HER2-positive biliary tract cancers, and optimally incorporate available agents into the clinical care of appropriately selected patients.
  • Review published and emerging research findings with HER2-targeted therapies for patients with HER2-positive gastroesophageal cancers, and assess the current and future role of various agents and regimens.
  • Recall available data with HER2-targeted agents and strategies for patients with previously treated HER2-overexpressing colorectal cancer, and optimally identify candidates who may be appropriate for these approaches.
  • Appraise the side effects associated with HER2-directed therapies with established efficacy in GI cancers, and use this information to develop supportive management plans for patients.
  • Recall the design of ongoing clinical trials evaluating novel HER2-directed strategies for HER2-positive GI cancers, and counsel appropriately selected patients about availability and participation.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Ellis — Advisory Committees: AstraZeneca Pharmaceuticals LP, Cogent Biosciences, Jazz Pharmaceuticals Inc; Honoraria: Incyte Corporation, Jazz Pharmaceuticals Inc; Nonrelevant Financial Relationships: Medscape, OncLive, The Jackson Laboratory. Prof Van Cutsem — Consulting Agreements: AbbVie Inc, Agenus Inc, ALX Oncology, Amgen Inc, Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeOne, BioNTech SE, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Cantargia, Daiichi Sankyo Inc, Debiopharm, Eisai Inc, ElmediX, Fosun Pharma, Galapagos NV, GSK, Incyte Corporation, Ipsen Biopharmaceuticals Inc, iTeos Therapeutics, Jazz Pharmaceuticals Inc, Johnson & Johnson, Lilly, Merck KGaA, MSD, Microbial Machines, Mirati Therapeutics Inc, Nordic Pharma, Novartis, Novocure Inc, Pfizer Inc, Pierre Fabre, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, Simcere, Taiho Oncology Inc, Takeda Pharmaceutical Company Limited, Trishula Therapeutics, Zymeworks Inc. Dr Wainberg — Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, EMD Serono Inc, Gilead Sciences Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Lilly, Merck, Novartis, Novocure Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Arcus Biosciences, Bristol Myers Squibb; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP, Pfizer Inc.

MODERATOR
Dr Kankeu Fonkoua has no conflicts of interest to disclose.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.

San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)

Directions
The San Francisco Marriott Marquis is located just 2 blocks (less than 0.2 miles) from the Moscone Center, where the 2026 ASCO Gastrointestinal Cancers Symposium is taking place.

 
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastrointestinal cancers.

No registration fee is charged for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.

NOTICE
Registration for this event is independent of registration for the 2026 ASCO Gastrointestinal Cancers Symposium.

IN-PERSON registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
 
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
WEBCAST registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Not an official event of the 2026 ASCO® Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.